MET and breast cancer: 1480 hepatocellular carcinoma (LIHC) cases had in 11 (0.7%) and 6 (0.4%) cases with amplification for the MET and FAM3C genes, respectively, in 5 cases with a shared amplification for both, 615 colorectal adenocarcinoma (COADREAD) cases showed CN amplification in 1 case (0.2%) shared for both MET and FAM3C and 1080 breast cancer (BRCA) cases had CN amplification in 10 cases (0.9%) for both MET and FAM3C, 7 sharing amplification for both (Supplemental Fig.S1A).